How can the US catch up on biosimilars? – MedCity News

Getty Images

Biosimilars are a growing share of the U.S. pharmaceuticals market. But while there are at least 240 biosimilars in the development pipeline, just nine have achieved FDA approval and only three have reached the market.

What needs to change for more biosimilars to enter the U.S. market?

Read the full story in MedCity News.

Advertisements

Inequality in medicine – Nature

Image: Zara Picken

Regulators have been calling for equal representation of men and women in health research for nearly 25 years. So why are women still underrepresented?

Read the full story in Nature

Cigall Kadoch | Innovators Under 35

A major vulnerability of certain kinds of cancer is becoming clear.

Problem:
The exact biochemical mechanisms involved in many kinds of cancer remain unknown.

Solution:
While completing her PhD at Stanford, Cigall Kadoch discovered a link between a genome regulator in cells called the BAF protein complex and a rare cancer called synovial sarcoma. She and colleagues later showed that mutations of BAF are involved in at least 20 percent of human cancers, opening the door for research on drugs that target mutated BAFs.

Read the full profile in MIT Technology Review.